BIG
TERN

Brooklyn Investment Group’s Terns Pharmaceuticals TERN Stock Holding History

Brooklyn Investment Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-145
Closed -$541 – 2472
2025
Q2 		$541 Buy
+145
New +$453 ﹤0.01% 3071
2025
Q1 		– Sell
-161
Closed -$892 – 2882
2024
Q4 		$892 Buy
+161
New +$1.09K ﹤0.01% 1619

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Brooklyn Investment Group's TERN Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Terns Pharmaceuticals (TERN) in Q3 2025, closing a stake of 145 shares — an estimated $541 sold.

Brooklyn Investment Group first reported a position in TERN in Q4 2024 and held it in 2 quarters. The position peaked at $892 in Q4 2024. 141 funds tracked by Wall St. Rank hold TERN as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Terns Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 145 Terns Pharmaceuticals shares in Q3 2025, an estimated $541.
  • Brooklyn Investment Group first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's Terns Pharmaceuticals position peaked at $892 in Q4 2024.
  • 141 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.